Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026

The European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026 delivered a mix of practice-informing and practice-questioning data across the gastrointestinal (GI) cancer landscape, from a phase 3 trial evaluating a KRAS G12C inhibitor combination that failed to beat chemotherapy in colorectal cancer to early phase 1/2 signals for a new RAS(ON) inhibitor in pancreatic cancer. Investigators also reported mixed results for chemoembolization-based combinations in hepatocellular carcinoma (HCC) and landmark long-term survival data for a checkpoint inhibitor doublet in refractory microsatellite-stable (MSS) colorectal cancer (CRC).